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Introduction and objectives: Infrainguinal bypass surgery (BPG) is accompanied by signiﬁcant 30-day
mortality and morbidity, including early graft failure. The goal of this study is to identify patient- and
procedure-speciﬁc factors which predict the rate of early graft failure in contemporary practice.
Methods: Data was obtained from the private sector National Surgical Quality Improvement Program,
a prospective, validated database collected between 2005 and 2008 from 211 hospitals, using primary
and modiﬁer Current Procedural Terminology codes for BPG. The primary endpoint was graft failure at 30
days. Procedural parameters, patient demographics and clinical variables were analyzed by univariate
and multivariate methods.
Results: There were 9217 BPG procedures (limb salvage, 49%; infrapopliteal distal anastomosis, 43%;
prosthetic 32%) with patient variables: age 67  12 years, male 64%, diabetes 44%, dialysis 7.4%. Mortality
was 2.4%, major morbidity was 17.3%, and graft failure rate was 6.3% at 30 days. Multivariate predictors of
graft failure demonstrated correlation (p-value, OR) with female gender (p ¼ 0.0054, 1.29), limb salvage
indication (p < 0.0001, 1.60), infrapopliteal anastomosis (p < 0.0001, 2.15), composite graft (p ¼ 0.0436,
1.82), current smoking (p ¼ 0.0007, 1.36), impaired sensorium (p ¼ 0.0075, 2.13), emergency procedure
(p < 0.0001, 2.03), previous vascular procedure (p ¼ 0.0005, 1.39), and platelets >400K (p ¼ 0.0019, 1.49).
High-risk composite constructs utilizing these signiﬁcant predictive factors can identify cohorts of
patients with up to a 98-fold increase in odds of early graft failure.
Conclusions: These results describe common risk factors that correlate with early graft thrombosis
including the unique description of its association with thrombocytosis. Additional risk factors thus
identify a subset of patients who are at highest risk for early BPG failure. This data may be used to reﬁne
patient selection.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Infrainguinal bypass surgery (BPG) has been shown to be asso-
ciated with signiﬁcant morbidity and mortality. Recent work has
demonstrated a 30-day mortality rate of 2.7%, and a major
complication rate of 18.7%. Earlier studies have elucidated some
patient and procedural factors which are associated with early and
late morbidity and mortality after BPG, including dyspnea, func-
tional dependence, renal failure, and limb salvage indication.1e6
Importantly, approximately 40% of major complications after BPG
are related to early graft failure.
Various studies have highlighted an incidence of early BPG
failure between 4.0 and 7.4%.2,7e9 While some evidence describing: þ1 617 724 1921.
Muraglia).
ciety for Vascular Surgery. Publisherisk factors for overall morbidity after BPG is available, the data
describing the speciﬁc complication of early BPG failure is some-
what more limited.1,5,10,11 The high incidence of early BPG failure is
concerning, especially given that little has been written regarding
the speciﬁc etiologic factors that predispose to this major
complication.
The advancing age of the population and the concomitant rise
in number of patients with peripheral arterial disease, coupled
with the increasing limitations on healthcare dollars make the
identiﬁcation of high-risk patient groups of paramount impor-
tance. Complications after BPG can lead not only to marked
increase in hospital costs, but these complications are also a poor
prognostic indicator for patient outcomes and limb salvage.12e19
Accordingly, the decision to undertake BPG, rather than non-
operative therapy or primary amputation, should be made while
carefully considering the associated peri-procedural morbidities,d by Elsevier Ltd. All rights reserved.
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outcomes.
The primary aim of this study is to identify patient-speciﬁc and
peri-procedural factors which may predict early BPG failure in
contemporary practice. This data, in turn, will be explored to iden-
tify the groups at highest risk for early BPG failure. Using this
information, the vascular surgeon will be able to improve patient
selection and reﬁne the treatment paradigm of lower extremity
occlusive disease, thus potentially minimizing BPG failure.
Methods
Patient population
From 2005 to 2008, as many as 211 hospitals participated in the
American College of Surgeons’ National Surgical Quality Improve-
ment Program (ACS-NSQIP). The ratio of academic to community
medical centers was approximately 3:2 throughout this time
period. Information from 635,265 patients was collected through
the ACS-NSQIP over these four years, and this data is contained in
the Participant Use File (PUF). After obtaining Institutional Review
Board (IRB) approval, this validated data source was queried by
Current Procedural Terminology (CPT) code to identify patients
undergoing any open BPG using either vein or prosthetic material
with a target of either the popliteal or tibial vessels (Table 1). These
codes are standardized numbers assigned to every service,
a medical practitioner may provide to a patient including medical,
surgical and diagnostic services. From within that cohort of
patients, an additional search for modiﬁer or adjunct CPT codes was
completed to delineate those patients who underwent BPG under
speciﬁc circumstances (i.e., re-do, arm vein harvest, etc) (Table 1).
Data set
The NSQIP data collection methodology has been previously
outlined.20e22 In summary, it is a validated, prospectively collectedTable 1
CPT codes.
Primary CPT Codes:
35556 Bypass graft with vein; femoral-popliteal
35566 Bypass graft with vein; femoral-tibial, peroneal, or other
distal vessels
35571 Bypass graft with vein; popliteal-tibial or tibial/peroneal
trunk-tibial
35583 In-situ vein bypass; femoral-popliteal
35585 In-situ vein bypass; femoral-anterior tibial, posterior tibial,
or peroneal
35587 In-situ vein bypass; popliteal-tibial, peroneal
35656 Bypass graft, other than vein; femoral-popliteal
35666 Bypass graft, other than vein; femoral-tibial or peroneal
35671 Bypass graft, other than vein; popliteal-tibial or peroneal
Modiﬁer/Adjunct CPT Codes:
35500 Harvest of upper extremity vein (1 segment) for lower
extremity bypass
35572 Harvest of femoropopliteal vein (1 segment) for vascular
reconstruction
35681 Bypass graft; composite, prosthetic and vein
35682 Bypass graft; autogenous composite, two segments of vein
(2 locations)
35683 Bypass graft; autogenous composite, three or more segments
(2 locations)
35685 Placement of vein patch/cuff at distal anastomosis of bypass;
synthetic conduit
35686 Creation of distal AV ﬁstula during lower extremity bypass
(non-hemodialysis)
35700 Reoperation, femoral-popliteal or femoral(popliteal)-tibial,
peroneal, other distal vessels, more than 1 month after
original operation
CPT ¼ Current Procedural Terminology.database containing clinical variables. The data represents
a systematic sample of each member-hospital’s caseload, and is
modiﬁed in order to be compliant with the Health Insurance
Portability and Accountability Act (HIPAA) by omitting hospital,
provider, or patient protected health information.21,23 In each
participating medical center, a dedicated surgical clinical nurse
reviewer is responsible for collecting pre-operative risk factors,
intra-operative variables, and 30-day post-operative mortality and
morbidity outcomes for patients undergoing major
procedures.20e22,24 During routine site visits, the completeness and
validity of the data are ensured.25
The pre-operative variables collected for the NSQIP describe the
patient’s demographic characteristics and their associated comor-
bidities for undergoing a variety of surgical procedures. The ACS-
NSQIP database captures information regarding common
outcomes for surgical procedures at 30 days. The information
collected is not procedure-speciﬁc, and thus speciﬁc vascular
surgical complications are not assessed.
Statistical analysis e univariate comparisons
The cohort of patients was divided into those who experienced
an early graft failure, and thosewho did not. The occurrence of graft
failure was determined by the response for the “graft failure”
variable entered by the independent nurse reviewers. The “graft
failure” variable is a validated data point collected by the NSQIP
nurse reviewers. The deﬁnition of this variable is: “Mechanical
failure of an extracardiac graft or prosthesis requiring return to the
operating room, interventional radiology, or a balloon angioplasty.”
While it is not speciﬁc to lower extremity bypass conduit for all
NSQIP patients, in the subset of patients undergoing lower
extremity bypass, this variable can be considered to speciﬁcally
refer to the vascular conduit.
Pre-operative, operative, and post-operative variables were
evaluated for these two groups. Post-operative variables include,
but are not limited to death, major morbidity, and any morbidity.
Major morbidity includes all of the measured outcomes, with the
exception of urinary tract infection, superﬁcial wound infection,
DVT, and peripheral nerve injury. For each comparison, the Fisher’s
Exact test was used for discrete variables, the t-test with equal
variances was used for normally distributed continuous variables,
and the Wilcoxon rank-sum test was used for non-normally
distributed continuous and ordinal variables.
Statistical analysis e multivariate modeling
The occurrence of early graft failure was modeled using step-
wise logistic regression. The number of candidate predictors was
determined by the frequency of graft failure within the cohort. In
addition to those variables that were deemed clinically relevant, all
pre-operative and demographic variables which were missing in
less than 10% of the patients AND which correlated with the
outcome of graft failure on univariate analysis (p < 0.15) were
considered for inclusion in the ﬁnal risk-adjustment model. Addi-
tionally, the CPT-deﬁned adjunct/modiﬁer variables which met the
same criteria were also considered for inclusion in the model. Of
note, none of these variables were forced into the multivariate
model. A signiﬁcance level of 0.05 was the threshold chosen for the
stepwise procedure, and thus was the threshold for a variable to
remain in the model.
For possible combinations of comorbidities (i.e., “high-risk
composites”), individual regression parameter estimates from the
multivariate model for early graft failure were used to calculate
composite odds ratios. These composite odds ratios demonstrate
the effects of a combination of comorbidities in a cluster.26
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Between January 1, 2005 and December 31, 2008, ACS-NSQIP
nurses entered data from 9217 lower extremity bypass proce-
dures, as deﬁned by primary CPT codes. Of these, 576 (6.3%) were
found to have failure of BPG within 30 days.
Patient characteristics
Table 2 presents a demographic comparison between the BPG
patients with and without early graft failure. This comparison
identiﬁes, by univariate methods, those clinical variables that are
signiﬁcantly different between these two groups. It shows a statis-
tically signiﬁcant difference between the two groups with respect
to age distribution (Failure ¼ 66.8  13.0 v. Patent ¼ 67.8  11.9,
p ¼ 0.02), gender distribution (with more females represented in
the early failure group; 41.1% v. 35.9%, p ¼ 0.01) and racialTable 2
Comparison of demographics, comorbidities, & laboratory parameters.
Variable Graft failure
(% unless
indicated)
n ¼ 576
No graft failure
(% unless
indicated)
n ¼ 8641
p-value
Male 58.9 64.1 0.012
White 66.8 72.2 0.006
Age (years) (mean  sd) 66.8  13.0 67.9  11.9 0.024
BMI (mean  sd) 27.2  6.0 27.4  6.3 0.390
EtOH use 5.9 5.9 1.000
Respiratory
Tobacco use 45.1 40.2 0.020
Dyspnea 19.6 18.8 0.620
COPD 12.7 12.7 1.000
Pneumonia 0.17 0.38 0.722
Cardiovascular
CHF in 30 days prior to surgery 3.1 2.9 0.702
MI in 6 months prior to surgery 2.4 2.1 0.551
Previous coronary intervention 17.9 18.5 0.740
Previous cardiac surgery 22.1 25.1 0.111
Angina in 1 month prior to surgery 2.4 2.3 0.771
HTN requiring medication 81.4 83.9 0.130
Revasc or Amp for PVD 65.6 55.7 <0.001
Rest pain or gangrene 64.1 48.3 <0.001
Renal
Acute renal failure 1.6 1.5 0.860
Dialysis 7.3 7.4 1.000
Neurologic
Impaired sensorium 3 1.1 <0.001
History of TIA 9 6.7 0.041
CVA with deﬁcit 8.7 7.5 0.290
CVA without deﬁcit 6.9 6.8 0.932
Hematologic/Oncologic/Endocrine
Diabetes 41.3 44.1 0.209
Steroid use for chronic condition 4.9 4.1 0.331
Bleeding disorder 23.3 23.2 0.959
Other
Functionally dependent 24.7 18.4 <0.001
Pre-op wound infection 42.5 37.8 0.027
Laboratory Parametersa
Albumin (g/dL) (mean  sd) 3.45  0.70 3.58  0.7 0.003
Albumin <3.0 g/dL (n ¼ 4454) 23.8 18.1 0.020
Abnormal BUN (n ¼ 8735) 8.6 7.7 0.413
Creatinine >1.5 (n ¼ 8906) 21 19.1 0.267
Hematocrit <27% (n ¼ 8934) 4.7 3.7 0.249
Hematocrit >45% 7.7 8.6 0.531
Platelets <150K (n ¼ 8878) 6.3 7.9 0.191
Platelets >400K 14.6 9 <0.001
BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; CHF:
Congestive Heart Failure; MI: Myocardial Infarction; HTN: Hypertension; PVD:
Peripheral Vascular Disease; TIA: Transient Ischemic Attack; CVA: Cerebrovascular
Accident; BUN: Blood Urea Nitrogen.
a Some laboratory values are missing. Sample size is listed along with variable
name.distribution (non-white race also proved to be a risk factor for early
graft failure; 33.2% v. 27.8%, p ¼ 0.01).
Table 2 also demonstrates the distribution of selected risk
factors/comorbidities among the groups. Those patients who went
on to early graft failure were more likely to be current smokers
(45.1% v. 40.2%, p¼ 0.02), and weremore likely to have limb salvage
as the indication for the procedure (64.1% v 48.3%, p < 0.01). As has
been shown previously, those patients who were classiﬁed as
functionally dependent were also more likely to suffer early graft
failure following BPG (24.7% v. 18.4%, p < 0.001). Furthermore, the
early failure group was more likely to have undergone a previous
procedure for peripheral ischemic disease (65.6% v. 55.7%, p< 0.01).
A history of transient ischemic attack, and an associated history of
impaired mental status were also found to be more common in
those suffering early graft failure. Despite this large sample size, the
remaining risk factors/comorbidities (i.e., major cardiac, respira-
tory, renal, or neurologic disease) were not found to be associated
with early BPG failure.
Various laboratory parameters were found to be associated with
early graft failure on univariate analysis. Table 2 displays the
comparison of relevant pre-operative laboratory results for both of
the BPG groups. Among those patients who did have laboratory
information available, the early failure group was more frequently
found to have an albumin <3.0 g/dL (23.8% v. 18.1%; p ¼ 0.02), and
they were also more likely to have a platelet count greater than
400,000 (14.6% v. 9.0%, p < 0.001).Operative details
Table 3 delineates the intra-operative characteristics according
to early failure status. Those patients in the early failure group were
more likely to be classiﬁed as “emergency” procedures (10.2% v.
5.4%, p < 0.001), and generally demonstrated longer operative
times (254 min v. 229 min, p < 0.001). Table 3 also describes the
technical parameters of the operation, as deﬁned by primary CPT
code and modiﬁer CPT codes. Those in the early graft failure group
were more likely to have a distal anastomosis inferior to the
popliteal artery (61.3% v. 42%, p< 0.001) and were more likely to be
undergoing a re-operative procedure (8.2% v. 5.7%, p ¼ 0.02). TheTable 3
Comparison of intra-operative characteristics.
Variable Graft failure
(% unless
indicated)
n ¼ 576
No graft failure
(% unless
indicated)
n ¼ 8641
p-value
Emergency case 10.2 5.4 <0.001
ASA 3 or higher 93.1 92.2 0.471
Operative time (min  sd) 254.2  119.6 229.1  103.6 <0.001
Bypass graft other than vein 31.9 31.5 0.853
Bypass graft e In-situ vein 15.6 12.9 0.064
Target vessel below popliteal 61.28 42 <0.001
Adjunct (any of the below codes) 15.45 12.26 0.027
Composite conduit (prosthetic
& vein)
2.43 1.19 0.019
Autogenous composite (2 vein
segments)
2.26 1.91 0.531
Autogenous composite (3þ vein
segments)
0.35 0.25 0.660
Vein patch/cuff at distal
anastomosis
2.43 1.31 0.039
Creation of distal AV ﬁstula 0.17 0.47 0.518
Redo >1 month after original
procedure
8.16 5.74 0.022
Harvest upper extremity 1.04 2.27 0.055
Harvest lower extremity 0.17 1.12 0.032
ASA: American Society of Anesthesiology class.
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graft failure (2.4% v. 1.3%, p ¼ 0.04); a fact that may suggest a poor
target vessel for bypass.
Univariate outcomes
The 30-day outcomes for the entire cohort (regardless of
patency status of BPG), and then the outcomes according to failure
group are presented in Table 4. The overall rate of graft failure at 30
days was 6.3%. The complete cohort demonstrated a high incidence
of return to the operating room within 30 days (19%), superﬁcial
surgical site infection (7.8%), and sepsis (3.5%). All other speciﬁc
complications occurred in less than 3% of patients.
When comparing the groups based on early failure status, it is
noteworthy that the early failure group demonstrated higher rates
of nearly every post-operative occurrence. No occurrencewas found
to be statistically more prevalent in the non-graft failure group.
Multivariate outcomes
Table 5 shows the result of a stepwise selection procedure used
to build a multivariate logistic regression model to identify the
major risk factors for early BPG failure. Based on the statistical
algorithm outlined previously, thirty-nine variables were identiﬁed
as candidate predictors for the modeling process. Because some
patients’ data elements were missing, only 7728 patients were
entered into themodel-building procedure. At the conclusion of the
selection process, nine variables retained statistical signiﬁcance,
and thus remained in the risk-adjustment model (Table 5). The c-
index for this predictive model is 0.671.
High-risk composites
Five of the statistically signiﬁcantmultivariate correlates of early
graft failure (infrapopliteal bypass target, bypass for limb salvage,Table 4
Comparison of 30-day outcomes e univariate results.
Variable Overall incidence (%) of occurrence
n ¼ 9217
Graf
n ¼
Post-Op LOS (median days [Q1, Q3]) 5.0 [3.0, 8.0] 8.0 [
Death 2.4 5.2
Any occurrence 20.8 40.1
Major occurrencea 13 30.7
Superﬁcial infection 7.8 11.5
Deep infection 2.9 7.3
Organ space infection 0.4 1.7
Wound dehiscence 1.7 3.3
Post-op pneumonia 1.7 3.8
Unplanned intubation 2 5.2
PE 0.1 0
On ventilator >48 h 1.7 5.4
Progressive renal insufﬁciency 0.6 1.2
Acute renal failure 0.5 1.4
Urinary tract infection 2.2 4.7
CVA with deﬁcit 0.6 1.2
Coma >24 h 0.1 0.4
Peripheral nerve injury 0.1 0.2
Cardiac arrest requiring CPR 1 2.4
MI 0.8 1.4
Bleeding requiring transfusion 1.2 4.7
DVT/thrombophlebitis 0.9 1.6
Sepsis 3.5 9.9
Septic shock 1.8 5.2
Return to OR within 30 days 19 84.2
LOS: Length of Stay; PE: Pulmonary Embolus; CVA: Cerebrovascular Accident; CPR: Cardio
OR: Operating Room.
a Major occurrence¼ any of the measured outcomes, with the exception of urinary trac
injury.platelets >400K, current smoker, composite bypass graft) were
deemed “actionable,” and thus were chosen for inclusion in high-
risk composite clusters. The odds of early graft failure for various
permutations of these peri-operative comorbidities were calcu-
lated, and the results are presented in Table 6. Discrete combina-
tions of these risk factors lead to a 2- to 12-fold increase in the odds
of early failure of BPG. The combination of all nine of the statisti-
cally signiﬁcant multivariate predictors of early BPG failure reveals
a subgroup of patients who experience a 98-fold increased odds of
early patency loss.
Discussion
This study reviewed data on all patients undergoing BPG taken
from the ACS-NSQIP data set from 2005 to 2008. These ﬁndings
describe results from a large and varied collection of hospitals,
including both academic and community medical centers. Ulti-
mately, this results in a representative sample of “everyday prac-
tice.” In this series, about half of the patients underwent BPG for an
indication of critical limb ischemia. Nearly one-half required
a distal anastomosis to an infrapopliteal target, and approximately
one-third required the use of a non-autogenous conduit.
In our analysis, we found nine patient-speciﬁc and procedure-
speciﬁc risk factors which are correlated with early graft failure
after BPG (see Table 5). To our knowledge, the identiﬁcation of
thrombocytosis as a potential risk factor for early graft failure is
a novel ﬁnding. With the identiﬁcation of the associated high-risk
composite groups, providers should be able to predict those at
highest risk for BPG failure.
Thrombocytosis may be either primary (i.e., myeloproliferative
disorder) or secondary (i.e., due to an inﬂammatory state or
neoplasm). Although primary thrombocytosis is less common, it is
associated with increased thrombosis, while secondary thrombo-
cytosis is variably associated with hypercoagulability. For instance,
thrombocytosis which is related to chronic myelogenous leukemia,t failure (% unless indicated)
576
No graft failure (% unless indicated)
n ¼ 8641
p-value
5.0, 13.0] 5.0 [3.0, 7.0] <0.001
2.2 <0.001
19.5 <0.001
11.8 <0.001
7.6 0.001
2.6 <0.001
0.4 0.001
1.6 0.004
1.6 <0.001
1.8 <0.001
0.1 1.000
1.5 <0.001
0.6 0.082
0.5 0.009
2.1 <0.001
0.6 0.082
0.1 0.049
0.1 0.321
1 0.002
0.8 0.139
0.9 <0.001
0.8 0.037
3 <0.001
1.6 <0.001
14.6 <0.001
pulmonary Resuscitation; MI:Myocardial Infarction; DVT: Deep Venous Thrombosis;
t infection, superﬁcial wound infection, DVT/thrombophlebitis, and peripheral nerve
Table 5
Multivariate predictors of early graft failure.
Variable Odds ratio (95% CI) p-value
Infrapopliteal bypass target 2.15 (1.79, 2.58) <0.001
Bypass for limb salvage 1.60 (1.33, 1.93) <0.001
Emergency procedure 2.03 (1.50, 2.73) <0.001
Prior operation for PVD 1.39 (1.16, 1.67) <0.001
Platelets >400K 1.49 (1.16, 1.92) 0.002
Current smoker 1.36 (1.14, 1.63) <0.001
Impaired sensorium 2.13 (1.22, 3.71) 0.008
Male 0.78 (0.65, 0.93) 0.005
Composite bypass graft 1.82 (1.02, 3.25) 0.044
c-statistic ¼ 0.671
n ¼ 7728. 1472 patients deleted due to missing variables.
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cytopenia is often associated with increased clot production.
Contrarily, thrombocytosis which is secondary to splenectomy is
generally not associated with hypercoagulability.27e32
The etiology of thrombocytosis is important when determining
how, if at all, to treat the elevated platelet count prior to BPG. In
cases of primary thrombocytosis, patients are often given aspirin or
hydroxyurea to normalize the platelet count and reduce hyperco-
agulability. However, in the setting of an elevated platelet count,
these may induce further bleeding or even higher rates of throm-
bosis depending on the clinical setting, and thus the clinical
scenario should be carefully evaluated. In cases of secondary
thrombocytosis, treatment of the underlying inﬂammatory or
neoplastic cause is often themost appropriate treatment of elevated
platelet count. In these patients, it may be judicious, if clinically
possible, to delay BPG until the etiology of the thrombocytosis can
be fully characterized or the underlying condition treated.
Previous studies have examined the question of early graft
failure on a large scale, speciﬁcally from the Veterans’ Affairs (VA)-
NSQIP and from the Vascular Study Group of Northern New
England (VSGNNE). Results from these groups, in many cases,
corroborate the present ﬁndings.Table 6
Odds of early graft failure for high-risk composite groups.
Risk factor combination OR
IP þ LS 3.44
IP þ PLT 3.20
IP þ SMK 2.92
IP þ CMP 3.91
LS þ PLT 2.38
LS þ SMK 2.18
LS þ CMP 2.91
PLT þ SMK 2.03
PLT þ CMP 2.71
SMK þ CMP 2.48
IP þ LS þ PLT 5.13
IP þ LS þ SMK 4.68
IP þ LS þ CMP 6.26
IP þ PLT þ SMK 4.36
IP þ PLT þ CMP 5.83
IP þ SMK þ CMP 5.32
LS þ PLT þ SMK 3.24
LS þ PLT þ CMP 4.34
LS þ SMK þ CMP 3.96
PLT þ SMK þ CMP 3.69
IP þ LS þ PLT þ SMK 6.97
IP þ LS þ PLT þ CMP 9.33
IP þ LS þ SMK þ CMP 8.51
IP þ PLT þ SMK þ CMP 7.93
LS þ PLT þ SMK þ CMP 5.90
IP þ LS þ PLT þ SMK þ CMP 12.69
IP ¼ Infrapopliteal Target; IP ¼ Infrapopliteal Target; LS ¼ Bypass
for Limb Salvage; PLT ¼ Platelets >400K; SMK ¼ Current Smoker;
CMP ¼ Composite Bypass Graft.Singh et al., conducted an evaluation of the VA-NSQIP from 1995
to 2003 to examine the issue of early failure after BPG, citing an
incidence of 4.9%. This data is taken from a 123 hospital consortium
of Veterans’ Affairs Medical Centers, and thus considered a some-
what different patient population. In this study, 99% of patients
were male, and they were more likely to use alcohol, and to be
current smokers. Multivariate analysis of this group demonstrated
that young age, African-American race, absence of diabetes, and
anemia were patient-speciﬁc factors related to early graft failure.
Additionally, a bypass to an infrapopliteal target was also found to
be a procedure-related risk factor for early failure after BPG.
Interestingly, the choice of conduit, and/or vein orientationwas not
found to be a signiﬁcant indicator of early graft patency.9
As in the study by Singh et al, the present study also demon-
strated that an infrapopliteal target is associated with a higher odds
of early BPG failure. Additionally identiﬁed predictors of early graft
failure, however, are somewhat different between the two studies.
This appears to be partially due to some differences in the available
data points. For instance, in the current study, it was noted that
bypass for limb salvage, emergency procedure, impaired senso-
rium, and prior operation for peripheral vascular disease (PVD)
were all associated with early graft failure. In contrast, these vari-
ables were not available or were not considered for the VA inves-
tigation. In addition, because of the time period during which data
was collected, the authors of the VA-NSQIP study did not have the
CPT codes for adjuvant procedures (i.e., distal AV ﬁstula, vein patch/
cuff, etc) available in their data set for analysis.
Other differences in the identiﬁed predictors of early graft
failure persist. Female gender is presently identiﬁed as a predictor
of graft failure, however the study from the VA-NSQIP would be
unable to detect such a correlation, as less than 1% of its partici-
pants were women. Similar to the present study, Singh et al. did
identify current smoking status as a univariate predictor of early
graft failure; however in their study, this correlation did not
maintain signiﬁcance on multivariate analysis. Again, this may be
due to the different populations studied, as there was a higher
incidence of smoking in the VA cohort compared to the current
study (53% v 40%). Finally, while they did not identify thrombocy-
tosis as a predictor of early graft failure, they did identify a statis-
tically signiﬁcant association between graft failure and anemia. The
reasons for this discrepancy are not apparent, however this may be
related to consideration of platelet count as a continuous, rather
than a binary variable.
The VSGNNE also recently examined predictors of early graft
failure after BPG.33 In that analysis, the primary endpoint was graft
occlusion or limb amputation at one year, as opposed to 30-day
graft occlusion in the current study. In the VSGNNE study, eight
factors were found to be associated with graft occlusion or ampu-
tation at one year: age<50, non-ambulatory status prior to surgery,
dialysis dependence, diabetes, critical limb ischemia, conduit
requiring venovenostomy, tarsal/distal/tibial target, and nursing
home residence pre-operatively. The present study also identiﬁed
critical limb ischemia and a distal infrapopliteal target anastomosis
as risk factors for early failure.
Some predictors of early graft failure that were identiﬁed in the
present study were not examined in the VSGNNE study, and
therefore would not have been demonstrated as predictors of graft
loss. Speciﬁcally, the patients’ pre-operative platelet count was not
reported, however that data set does contain information on
patient use of anti-platelet medications. It is interesting to note that
on univariate analysis those patients who were using anti-platelet
medications at the time of BPG were signiﬁcantly less likely to
suffer graft occlusion at one year than those who were not taking
these medications (12% v. 15%, p ¼ 0.048). This difference was not
persistent through multivariate analysis, however.
R.T. Lancaster et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 549e555554The present study is somewhat more generalizable than the
VSGNNE analysis, which is limited to 60 surgeons from 11 hospitals,
uses self-reported outcomes, and encompasses a patient pop-
ulation that is somewhat less racially diverse. That study does,
however, enjoy the beneﬁt of being derived from a Vascular
Surgery-speciﬁc quality-improvement initiative, and thus uses pre-
operative and post-operative data which is speciﬁc to vascular
surgical procedures. This is in contrast to the current study, which is
derived from a quality-improvement initiative, which is not speciﬁc
to vascular surgical procedures.
The results from the current study identify subgroups of
patients which are at increased risk for early failure after BPG, and
composites of these risk factors can be combined to identify high-
risk groups. For instance, a patient undergoing BPG who has
thrombocytosis and requires a composite graft to reach an infra-
popliteal target has a nearly 6-fold increased odds of early graft
failure, when compared to a similar patient with normal platelets
who receives a non-composite graft to reach a supra-geniculate
target. Although this is not indicative for any speciﬁc patient, the
information about these composite high-risk groups can be incor-
porated into the vascular surgeon’s decision-making process, and
thus may inform patient- or procedure selection. This reﬁned
patient selection, may in turn, yield improved early failure rates
after BPG.
There are some limitations to this study. First, only the speciﬁc
outcome of graft failure at 30 days is evaluated. Measures of patient
quality of life or satisfaction, while relevant, are not availablewithin
this data set. Also, the NSQIP data points are, by design, quite
general in order to allow for comparisons across many surgical
procedures. There are no pre-operative, intra-operative or post-
operative variables that are speciﬁc to vascular surgical procedures.
Furthermore, given the 30-day limitation to collected outcomes,
and the lack of vascular-speciﬁc endpoints, the NSQIP data cannot
be used to assess important long-term results, such as limb salvage.
Finally, approximately 16% of the patients evaluated were missing
at least one data point relevant to the multivariate model, and thus
were not included in the model. No differences in outcome were
noted between those with and without missing data, so these data
points are believed to be missing at random.
Recently, quality-improvement initiatives, such as the VSGNNE,
have been developed that will collect vascular surgery-speciﬁc
variables in order to assess complications as well as clinical efﬁcacy.
These entities should provide important risk-adjusted, procedure-
speciﬁc, long-term data that includes clinical efﬁcacy as well as
safety.
Another limitation is that the risk adjustment appears to have
limited discriminatory abilities, as the c-statistic for this model is
0.671. This value reﬂects the fact that peripheral arterial disease is
multi-factorial, affecting many different organ systems, and likely
stems from many different psychological, socioeconomic, and
physiologic pathways, and thus cannot be completely explained by
the elements of the data set. The addition of procedure-speciﬁc
variables, or other variables that were not collected here, could
improve the discriminatory power of the risk-adjustment model.
Despite the aforementioned limitations, the strength of this
study is that multi-institutional, clinically rich data, from over 200
hospitals, based on standardized deﬁnitions and collected by
audited trained surgical clinical nurse reviewers, was compared for
9217 lower extremity bypass procedures. Measurement bias and
publication bias are therefore minimized.
Conclusions
In conclusion, we identiﬁed ﬁve patient-speciﬁc risk factors
(previous operation for PVD, current smoker, thrombocytosis[>400K], impaired sensorium, female gender) and four procedure-
speciﬁc risk factors (indication of limb salvage, distal target,
emergency procedure, composite bypass graft) that are associated
with early graft failure. The identiﬁcation of thrombocytosis is
a novel risk factor in predicting early graft failure. When these
variables are identiﬁed pre-operatively for a given patient, the
increased risk of early BPG failure should be considered in clinical
decision-making.
It is believed that this data will inform patient-selection prac-
tices for a wide range of vascular surgeons. This aid in identifying
high-risk patients may lead to a lower incidence of early graft
failure after BPG through more reﬁned patient selection.
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